EE316 The Cost-Saving of the Introduction of Dapagliflozin in Algeria After Primary Failure of Oral Anti-Diabetics in Patients With Types 2 Diabetes (T2DM)
In diabetes treatment, type 2 sodium-glucose cotransporter (SGLT2) inhibitors have emerged as a substantial advancement in terms of effectiveness and cost-efficiency. In order to introduce Dapagliflozin (Valens ®) into the Algerian market, a cost-saving evaluation was conducted to evaluate the clinical outcomes and financial implications of using Dapagliflozin after the primary failure of oral antidiabetics for treating patients with type 2 diabetes(T2DM).
Source: Value in Health - Category: International Medicine & Public Health Authors: A. Aburmilah, Y. Hammas, N. Nouri, N. Oulmane, M. Yala, A. Yala Source Type: research
More News: Algeria Health | Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Forxiga | International Medicine & Public Health | SGLT2 Inhibitors | Sodium